Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

BOSTON — In the staging of liver fibrosis in the post-liver transplant setting, readings from noninvasive tests commonly have major discrepancies when compared with liver biopsy results, particularly ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...

Juanhua Wu, Yunyang Chen, Chaohai Zuo, Naile Kuang, Ronggang Li, Qing Li, Jianqiu Ruan, Enming Cui, Ruiyun Xu, Jiexiong Yu https://www.jstor.org/stable/27043056 Copy ...

The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...

Patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis who received a novel small molecule thyroid hormone receptor agonist achieved statistically ...

Resolution of steatohepatitis with no worsening of liver fibrosis was achieved in 63% of patients taking semaglutide vs 34% taking placebo at week 72. The Food and Drug Administration (FDA) has ...

At the Liver Meeting sponsored by the American Association for the Study of Liver Diseases, investigators presented new ...

Semaglutide met both primary endpoints in part 1 of ESSENCE. Topline results were announced from part 1 of a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with metabolic ...

Gyre Therapeutics announced positive results from its Phase 3 trial of Hydronidone, a treatment for liver fibrosis in patients with chronic hepatitis B (CHB), showing a significant regression in ...